Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 11;14(1):7.
doi: 10.1007/s13679-024-00597-6.

Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management

Daniel Simancas-Racines  1 , Giuseppe Annunziata  2 , Ludovica Verde  3 , Federica Fascì-Spurio  4 , Claudia Reytor-González  5 , Giovanna Muscogiuri  6   7   8 , Evelyn Frias-Toral  9 , Luigi Barrea  10
Affiliations
Review

Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management

Daniel Simancas-Racines et al. Curr Obes Rep. .

Abstract

Purpose of review: This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine the effectiveness of specific nutritional strategies in preventing and treating this obesity-linked liver disease.

Recent findings: Emerging evidence underscores the benefits of the Mediterranean diet, low-carbohydrate diets, and intermittent fasting in reducing liver fat, improving insulin sensitivity, and mitigating inflammation. Supplementing with vitamin E, omega-3 fatty acids, and silymarin can potentially reduce liver fibrosis and promote liver health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, and nutraceutical supplementation. Integrating these strategies with lifestyle modifications, including regular physical activity, offers a comprehensive approach to improving metabolic and liver outcomes in patients with MASLD. Further research is needed to refine and personalize these therapeutic interventions.

Keywords: Liver fibrosis; Medical Nutritional Therapy (MNT); Mediterranean diet; Metabolic-Associated Steatotic Liver Disease (MASLD); Nutraceutical supplementation; Obesity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
Selective insulin resistance and the impact of hyperinsulinemia on hepatic lipogenesis and gluconeogenesis. Chronic hyperinsulinemia is a hallmark of insulin resistance, which is selective rather than uniform. While certain insulin signaling pathways are impaired, others remain sensitive and become overstimulated due to elevated insulin levels. In the liver, pathways involved in gluconeogenesis and glycogen synthesis become resistant to insulin, whereas the lipogenic pathway remains insulin-sensitive. This selective sensitivity leads to overstimulation of lipogenesis, resulting in hepatic fat accumulation
Fig. 2
Fig. 2
Main lifestyle interventions and nutritional goals for the management of MASLD. The solid lines in the boxes represent evidence from studies specifically conducted on patients diagnosed with MASLD. The dashed lines indicate interventions that have been proposed or may be beneficial in managing MASLD, but for which specific studies on this patient group are lacking. The half-dashed, half-continuous box represents evidence that requires further confirmation. Abbreviations: GFD, gluten-free diet; VLEKT, very low-energy ketogenic therapy; MD, Mediterranean Diet; IF, intermittent fasting; VegD, vegetarian diet; MNT, medical nutrition therapy; Vit D-E-C, Vitamins D, E, and C; CGA, chlorogenic acid; Cur, curcumin; RSV, resveratrol; HIIT, high-intensity interval training; INF, inflammation; OxS, oxidative stress; MASLD, metabolic-associated steatotic liver disease
See this image and copyright information in PMC

References

    1. World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
    1. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21). 10.1161/CIR.0000000000000973 - PMC - PubMed
    1. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14. 10.3389/fendo.2023.1161521 - PMC - PubMed
    1. Li Y, Pan A, Wang DD, et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018;138(4):345–55. 10.1161/CIRCULATIONAHA.117.032047. - PMC - PubMed
    1. Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30. 10.1016/S2468-1253(22)00317-X. - PubMed

Substances